Ameriprise Financial Inc. Purchases 23,608 Shares of Humana Inc. $HUM

Key Points

• Ameriprise Financial Inc. raised its stake in Humana Inc. by 13.4% during the first quarter, now holding 199,932 shares worth approximately $52.92 million.
• Humana's recent quarterly earnings showed a missed EPS estimate of $6.27 compared to the consensus of $6.32, while revenue exceeded expectations at $32.39 billion.
• The company declared a quarterly dividend of $0.885, with an annualized dividend yield of 1.2%, to be paid on October 31st.

Ameriprise Financial Inc. lifted its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 13.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 199,932 shares of the insurance provider's stock after purchasing an additional 23,608 shares during the quarter. Ameriprise Financial Inc. owned 0.17% of Humana worth $52,918,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of HUM. Revolve Wealth Partners LLC acquired a new stake in Humana in the 4th quarter valued at approximately $202,000. Northern Trust Corp boosted its stake in Humana by 14.5% in the 4th quarter. Northern Trust Corp now owns 1,216,195 shares of the insurance provider's stock valued at $308,561,000 after purchasing an additional 153,739 shares during the period. PDT Partners LLC boosted its stake in Humana by 118.7% in the 4th quarter. PDT Partners LLC now owns 8,881 shares of the insurance provider's stock valued at $2,253,000 after purchasing an additional 4,821 shares during the period. Triumph Capital Management grew its holdings in shares of Humana by 64.4% during the 4th quarter. Triumph Capital Management now owns 1,639 shares of the insurance provider's stock worth $416,000 after purchasing an additional 642 shares in the last quarter. Finally, Solel Partners LP acquired a new stake in shares of Humana during the 4th quarter worth $1,116,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Stock Up 2.0%

Shares of NYSE:HUM traded up $6.01 during mid-day trading on Monday, hitting $303.90. 1,099,760 shares of the company traded hands, compared to its average volume of 1,366,524. The stock has a market cap of $36.55 billion, a P/E ratio of 23.32, a P/E/G ratio of 1.79 and a beta of 0.44. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $382.72. The stock has a 50-day moving average price of $254.43 and a two-hundred day moving average price of $254.59.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. On average, equities research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.2%. Humana's payout ratio is currently 27.17%.

Analysts Set New Price Targets

Several brokerages recently weighed in on HUM. Piper Sandler dropped their price objective on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research report on Thursday, July 31st. Robert W. Baird lowered their price objective on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research report on Friday, July 25th. Bank of America lowered their price objective on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research report on Tuesday, June 17th. Wells Fargo & Company lowered their price objective on Humana from $348.00 to $344.00 and set an "overweight" rating for the company in a research report on Thursday, August 14th. Finally, Truist Financial lowered their target price on Humana from $280.00 to $260.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Seven equities research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $283.29.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.